Concepedia

Jung‐Min Lee

JL

24

Publications

1.7K

Citations

17

H-Index

2004

Active since

Affiliations

National Cancer Institute(Current)

Catholic University of Korea

National Institutes of Health

Dana-Farber Cancer Institute

Chungnam National University

Jung‐Min Lee is an author at National Cancer Institute specializing in medicine, ovarian cancer, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2004–2023

24

Publications

24

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer et al. · The Lancet Oncology · 2018 · 210 citations · Full text

, , +6

CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells

In-Young Jung, Yoon-Young Kim, Ho-Sung Yu et al. · Cancer Research · 2018 · 210 citations · Full text

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 209 citations · Full text

Establishment of Blood Glucose Monitoring System Using the Internet

Hyuk‐Sang Kwon, Jae‐Hyoung Cho, Hee‐Soo Kim et al. · Diabetes Care · 2004 · 199 citations

The long-run impact of a traumatic experience on risk aversion

Young Il Kim, Jung‐Min Lee · Journal of Economic Behavior & Organization · 2014 · 193 citations

, , +6

Rows per page

1–5 of 24